Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleTLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition.AuthorsStarr, PhoebeAbstractThe article reports on the use of investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) to reverse resistance to anti-PD-1 therapy.SubjectsPEMBROLIZUMAB; CANCER treatmentPublicationOncology Practice Management, 2018, Vol 8, Issue 9, p37ISSN2164-4403Publication typeArticle